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Abstract 
Introduction 
Colorectal cancer (CRC) arises in the tissue that lines the inner surface of the 
intestine (colon and rectum). Nivolumab received accelerated approval by the 
US Food and Drug Administration (FDA) in July 2017 for the following in-
dication: as monotherapy for the treatment of patients that are 12 years and 
older with DNA mismatch repair-deficient (dMMR) and microsatellite in-
stability-high (MSI-H) metastatic CRC that have progressed following 
treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. The FDA 
approval was based on one part of the CheckMate 142 study. Currently, 
nivolumab is not approved for CRC in Europe. 
Methodology 
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer (overall: 125 references). Quality assessment to 
assess the risk of bias at the study level based on the EUnetHTA internal va-
lidity was not conducted, since this tool is only for randomised controlled 
trials. Furthermore, the magnitude of clinically meaningful benefit that can 
be expected from nivolumab was evaluated based on the Magnitude of Clin-
ical Benefit Scale v1.1 (MCBS) developed by the European Society for Medi-
cal Oncology (ESMO). 
Results from the CheckMate 142 study 
The CheckMate 142 study is separated into two parts, investigating 
nivolumab monotherapy or nivolumab in combination with ipilimumab. 
The part of the study examined in the present report was conducted to assess 
the activity and safety of nivolumab monotherapy in 74 patients with meta-
static dMMR/MSI-H CRC. At the time of data cut-off (3 January 2017), 23 
(31.1%) of the 74 included patients demonstrated an objective response 
(OR) – all responses were partial (investigator-assessed). An OR assessed by 
blinded independent central review (BICR) occurred in 24 (32%) patients 
(dMMR/MSI-H per local assessment); out of those, 2 (3%) patients had a 
complete response and 22 (30%) a partial one. After 36 investigator-assessed 
progression events had happened, the median progression-free survival 
(PFS) was 14.3 months, but was not mature at the time of data cut-off. In 
addition, median overall survival (OS) (23 deaths) had not been reached at 
the time of interim analysis. In regard to safety outcomes, drug-related ad-
verse events (AEs) occurred in 70% of patients; out of those, 20% of patients 
had grade ≥3 AEs (most frequent: increased lipase and amylase). Serious 
AEs related to the study treatment of grade 3 or higher occurred in 12% of 
patients.  
Conclusion 
In conclusion, the treatment of nivolumab offers durable responses; 31.1% 
demonstrated partial responses with an acceptable safety profile at high 
costs. However, the immature OS data, in combination with the lack of evi-
dence for the actual patient population affected most by CRC in clinical 
practice, highlight the requirement for long-term data. Moreover, head-to-
head comparisons will be necessary to identify the best treatment option for 
CRC patients with dMMR/MSI-H. Finally, trustworthy biomarker testing 
will be needed to select those patients who benefit most from nivolumab.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is nivolumab? 
A0022 Who manufactures nivolumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has nivolumab received marketing authorisation? 
Health problem and current use 
A0002 What is colorectal cancer? 
A0004 What is the natural course of colorectal cancer? 
A0006 What are the consequences of colorectal cancer for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of colorectal cancer? 
A0003 What are the known risk factors for colorectal cancer? 
A0024 
How is colorectal cancer currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is colorectal cancer currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of nivolumab on mortality? 
D0005 
How does nivolumab affect symptoms and findings (severity, frequency) of colorectal 
cancer? 
D0006 How does nivolumab affect progression (or recurrence) of colorectal cancer? 
D0011 What is the effect of nivolumab on patients ̕ body functions? 
D0012 What is the effect of nivolumab on generic health-related quality of life? 
D0013 What is the effect of nivolumab on disease-specific quality of life? 
Safety 
C0008 How safe is nivolumab in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying nivolumab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of nivolumab? 
A0021 What is the reimbursement status of nivolumab? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Nivolumab/Opdivo
®
/L01XC17 
 
B0001: What is nivolumab? 
The programmed cell death receptor-1 protein (PD-1) is expressed on sever-
al cell types such as T-cells, B-cells, monocytes and natural killer cells [2]. 
The binding of the two known ligands of PD-1, PD-L1 and PD-L2, results in 
the inhibition of T-cell proliferation and cytokine production [2, 3]. There-
fore, the interaction of PD-1 with its ligands inhibits T-cell receptor signal-
ling as well as downregulates T-cell response [2]. Nivolumab is a human 
immunoglobulin G4 (IgG4) monoclonal antibody that blocks binding of PD-
1 to PD-L1 and PD-L2. Since PD-L1 is upregulated in some tumours, the 
blockade of these interactions can retrieve T-cell activity and cell-mediated 
immune response against these tumour cells [2, 3].  
Nivolumab monotherapy is administered as an intravenous infusion over 60 
minutes at a dose of 3 mg per kilogram of body weight every two weeks [4] 
 
A0022: Who manufactures nivolumab? 
Bristol-Myers Squibb 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Nivolumab is indicated for the treatment of patients with DNA mismatch 
repair-deficient (dMMR) or microsatellite instability-high (MSI-H) meta-
static CRC, who have progressed on or after, or been intolerant of at least 
one previous line of treatment, including fluoropyrimidine and oxaliplatin 
or irinotecan. 
 
 
 
 
nivolumab is a human 
IgG4 monoclonal 
antibody against PD-1 
intravenous infusion 
every two weeks 
dMMR/MSI-H 
metastatic CRC 
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4 Current regulatory status 
A0020: For which indications has nivolumab received marketing authorisa-
tion? 
To date, nivolumab is not approved for the treatment of patients with 
dMMR and MSI-H metastatic CRC by the European Medicines Agency 
(EMA). The EMA granted marketing authorisation of nivolumab for the fol-
lowing indications [5]: 
 for the treatment of NSCLC that has spread locally or to other parts 
of the body, in patients who have previously been treated with 
chemotherapy (February 2016) 
 for the treatment of advanced RCC as monotherapy in previously 
treated patients (April 2016) 
 for the treatment of advanced melanoma as monotherapy or in 
combination with ipilimumab (May 2016) 
 for the treatment of adult patients with relapsed or refractory cHL 
after autologous stem cell transplant and treatment with brentuxi-
mab vedotin (October 2016) 
 for the treatment of SCCHN as monotherapy in adults progressing 
on or after platinum-based therapy (April 2017) 
 for the treatment of locally advanced unresectable or metastatic UC 
as monotherapy in adults after failure of prior platinum-containing 
therapy (June 2017) 
In July 2017, the US Food and Drug Administration (FDA) granted acceler-
ated approval for nivolumab for the treatment of patients who are 12 years 
and older with dMMR and MSI-H metastatic CRC that have progressed fol-
lowing treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. The 
approval was based on the CheckMate 142 study. Moreover, nivolumab has 
received marketing authorisation by the FDA for several other indications 
[3]: 
 for the treatment of BRAF V600 wild-type unresectable or metastat-
ic melanoma as monotherapy (September 2015) 
 for the treatment of BRAF V600 mutation-positive unresectable or 
metastatic melanoma as monotherapy (September 2015) 
 for the treatment of unresectable or metastatic melanoma in com-
bination with ipilimumab (September 2015) 
 for the treatment of metastatic NSCLC patients, who have pro-
gressed on or after receiving platinum-based chemotherapy (Octo-
ber 2015) 
 for the treatment of advanced RCC patients, who have received pri-
or anti-angiogenic therapy (November 2015) 
 for the treatment of patients with cHL who relapsed or progressed 
after: 
not approved for 
metastatic CRC by the 
EMA, but for various 
other indications 
accelerated FDA 
approval for CRC in July 
2017 
 
additional approved 
indications of 
nivolumab in the US 
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o autologous hematopoietic stem cell transplantation 
(HSCT) and brentuximab vedotin, or 
o three or more lines of systemic therapy that includes au-
tologous HSCT (May 2016) 
 for the treatment of patients with recurrent or metastatic SCCHN 
with disease progression on or after a platinum-based therapy (No-
vember 2016) 
 for the treatment of previously treated locally advanced or metastat-
ic UC (February 2017) 
 
 
 
5 Burden of disease 
A0002: What is colorectal cancer? 
CRC is a malignancy that arises in the tissue that lines the inner surface of the 
intestine (colon and rectum). More than half (62%) of all bowel cancers arise 
from the colon and almost one-third (29%) arise from the rectum (including 
the anus) [6, 7]. Histologically, CRC can be differentiated into: adenocarci-
nomas, squamous cell carcinomas, carcinoid tumours, sarcomas, and lym-
phomas [7]. 
Generally, a large proportion of CRC tumours are characterised by the activa-
tion of the wnt/B-catenin pathway. In cases of metastatic diseases over 50% of 
patients carry RAS (KRAS or NRAS) mutations and in 5–10% of patients 
BRAF mutations are present. Furthermore, HER-2 amplifications occur in 2–
5% of CRCs [8]. A subset of CRCs demonstrate markedly elevated mutational 
rates; these are mainly tumours characterised by MSI-H, which is associated 
with inactivating alterations in MMR genes [8, 9]. In general, MSI-H tumours 
account only for a minority of CRCs, whereby the frequency decreases in more 
advanced stages of the disease. A small proportion of hyper-mutated CRC tu-
mours are seen to have polymerase mutations, especially within the catalytic 
domain of DNA polymerase epsilon (POLE) or delta (POLD1) [8]. 
 
A0004: What is the natural course of colorectal cancer? 
Mostly, CRC starts as a flat or raised polyp in the tissue that lines the inner 
surface of the colon or rectum. It can spread by lymphatic and haematog-
enous dissemination, as well as by contiguous and transperitoneal routes. In 
the majority of instances metastatic sites occur in the regional lymph nodes, 
liver, lungs, and the peritoneum [6].  
The preferred staging system for CRC is the tumour, node, metastasis (TNM) 
staging system of the combined American Joint Committee on Cancer 
(AJCC)/Union for International Cancer Control (UICC). It classifies tu-
mours on the basis of primary tumour characteristics (T), the presence or 
absence of regional lymph node involvement (N), and the presence or ab-
sence of distant metastases (M). The final stage (ranging from I to IV) is de-
pendent on the particular combination of T, N, and M characteristics [10]. 
CRC arises in the tissue 
of the inner surface of 
the colon or rectum 
various genetic subtypes 
of CRC 
commonly CRC arises as 
a flat or raised polyp in 
the colon or rectum 
prevalence of MSI-H: 
22% stage II 
12% stage III 
3% stage IV 
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The prevalence of MSI-H in the stages II, III and IV for CRC is 22%, 12%, 
and 3%, respectively [8]. 
MSI results from germline (inherited) or somatic (sporadic; acquired) muta-
tions. DNA mismatch errors are usually repaired by mismatch repair pro-
tein complexes. If these do not function, DNA errors accumulate, which is a 
condition of genetic hypermutability, like in the case of MSI [11]. On the 
contrary, dMMR deficiency is not a direct transforming event, since most 
oncogenic alterations found in dMMR patients have originated from somatic 
mutation events occurring as a result of MSI [9]. 
 
A0006: What are the consequences of colorectal cancer for the society? 
Due to the ageing population and in combination with the fact that higher 
age is related to increased CRC risk, the incidence of cancer will grow over 
time [12, 13]. Globally, CRC is the third most common cancer, with almost 
1.4 million new cases diagnosed in 2012 [14]. In addition, low socioeconomic 
status is associated with an increased risk for the development of CRC. The 
incidence of CRC varies more than tenfold worldwide. Socioeconomic dis-
parity particularly in the new-onset risk of CRC may be due to modifiable 
behaviours like physical inactivity, unhealthy diet, smoking, and obesity 
[13].  
 
A0023: How many people belong to the target population? 
Carcinomas of the colon and rectum are the third leading cause of death in 
men (13%) and the second leading cause of death in women (11%) due to 
cancer in Austria (2014). Two-thirds of all diagnosed intestine cancers oc-
curred in the colon, 30% in the rectum, and all others in the transition of the 
colon and rectum or the anal canal (small intestine carcinomas are not in-
cluded). In 2014, 4,567 new cases of colon and rectum cancer (men: 2,585; 
women: 1,982) were diagnosed in Austria, with a corresponding age stand-
ardised incidence rate for the European Standard Population of 55.0 cases 
per 100,000 persons [15]. The median age at diagnosis of CRC is 73 years in 
men and 75 in women (range: 70–75) [16]. 
One in five patients with CRC (20%) is present with metastatic disease at 
the time of diagnosis and the survival rate of CRC patients with distant me-
tastasis is about 12% [10, 17]. In approximately 15% of CRCs the tumour 
subtype MSI-H is represented, and only 3% of all CRCs have a germline 
MMR mutation (Lynch syndrome) [8, 9]. As a result, about 700 of the 4,567 
persons diagnosed with CRC in 2014 in Austria were affected by dMMR 
and/or MSI-H. 
 
A0005: What are the symptoms and the burden of colorectal cancer? 
The majority of CRC patients with an early stage of cancer do not show any 
characteristic symptoms or signs [10, 16]. If symptoms are present, they typ-
ically occur because of the tumour growth into the lumen or nearby struc-
tures; therefore, a symptomatic representation usually reflects relatively ad-
vanced cancer. However, CRC patients may be presented in the following 
three ways: suspicious symptoms and/or signs, asymptomatic individuals 
discovered by routine screening, and emergency admission with intestinal 
obstruction, peritonitis or, rarely, acute gastrointestinal bleeding [10].  
MSI arises from 
germline or somatic 
mutations 
increasing incidence 
 of CRC 
 
association with the 
socioeconomic status 
incidence rate of CRC: 
55.0 per 100,000 
persons/year (European 
Standard Population) 
 
median age at diagnosis 
in years: 
♂ 73 
♀ 75 
metastatic disease: 20% 
MSI-H: 15% 
MMR: 3% 
early stage of cancer is 
often asymptotic 
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A0003: What are the known risk factors for colorectal cancer? 
In general, environmental as well as genetic factors can increase the proba-
bility of developing CRC. The predominant risk factors for developing CRC 
are the following: hereditary forms of CRC, age, personal or family history 
of sporadic CRC, inflammatory bowel disease, and a history of abdominal 
irradiation [13]. Further, factors that may have an impact on the risk of 
CRC are cigarette smoking, alcohol, and obesity [18]. 
 
A0024: How is colorectal cancer currently diagnosed according to published 
guidelines and in practice? 
CRC may be suspected due to the aforementioned symptoms (A0005) or in 
cases of asymptomatic CRC it may be detected by routine screening [10]. In-
itial diagnosis is a digital rectal examination, primarily via a colonoscopy 
(including biopsy); if this is not applicable a rectoscopy/sigmoidoscopy (in-
cluding biopsy), or virtual colonoscopy may be applied. To evaluate the 
spread of the disease and to plan the next steps of treatment, a sonography, a 
computed tomography (CT) or a magnetic resonance imaging (MRI) of the 
abdomen or the thorax can be used [10, 16]. After an established diagnosis, 
the determination of the extent of the primary tumour and of the metastasis 
is based on the TNM staging system. Additionally, serum carcinoembryonic 
antigen (CEA) levels may be obtained preoperatively and postoperatively in 
patients with demonstrated CRC to support surgical treatment planning and 
prognosis assessment [16]. 
 
 
 
6 Current treatment 
A0025: How is colorectal cancer currently managed according to published 
guidelines and in practice? 
Certain factors have to be taken into account for the therapeutic decision on 
CRC [16, 19]:  
 Localisation of the primary tumour 
 Stage of cancer (TNM staging system) 
 Mutations in certain genes (e.g., MSI, BRAF, Lynch syndrome) 
 Health condition of the patient (Eastern Cooperative Oncology 
Group [ECOG] performance scale) 
Stage I, II or III CRC is commonly treated by surgical resection with cura-
tive intent. Adjuvant chemotherapy (5-fluorouracil, folinic acid, capecita-
bine, oxaliplatin) should be considered if a higher risk of recurrence is pre-
sent. This includes mostly patients with stage III (node-positive) CRC, 
whereas in cases of CRC patients with MSI, no adjuvant chemotherapy is 
recommended. Therapy options for stage IV CRC patients are [16, 19]: 
 Resectable metastasis 
o Chemotherapy (FOLFOX in combination with oxaliplatin 
or irinotecan) 
generally, 
environmental & 
genetic risk factors 
initial diagnosis: 
colonoscopy (+ biopsy), 
rectoscopy/ 
sigmoidoscopy  
(+ biopsy), and virtual 
colonoscopy 
factors for therapeutic 
decision 
stage I, II, III treatment 
 
 
 
therapy options for 
stage IV CRC: 
 
for resectable and 
unresectable metastasis 
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 Unresectable metastasis 
o RAS or BRAF mutation 
 fluoropyrimidine plus oxaliplatin and/or iri-
notecan with or without bevacizumab 
o RAS or BRAF wild-type 
 fluoropyrimidine plus oxaliplatin or irinotecan in 
combination with an anti-EGFR antibody (cetux-
imab, panitumumab) 
o Patients with severe comorbidities 
 5-fluorouracil or capecitabine in combination 
with bevacizumab or best supportive care 
 ≥Second-line therapy options (dependent on prior therapy and the 
RAS mutation status) [16, 19]: 
o Prior irinotecan-based therapies  oxaliplatin in combi-
nation with fluoropyrimidine; if prior irinotecan therapy 
did not include bevacizumab  FOLFOX in combination 
with bevacizumab 
o Prior oxaliplatin  fluoropyrimidine in combination with 
irinotecan 
o Prior oxaliplatin-based therapies  FOLFIRI chemother-
apy in combination with aflibercept 
o Prior bevacizumab- or oxaliplatin-based therapy  ramu-
cirumab in combination with FOLFIRI 
o RAS wild-type patients who have not received an EGFR 
antibody  EGFR antibody in combination with chemo-
therapy 
o Failure of all established chemotherapies and monoclonal 
antibodies  regorafenib or fluoropyrimidine TAS 102 
o BRAF mutation  vemurafenib in combination with ce-
tuximab/irinotecan 
o MSI mutations  off-label use of pembrolizumab and 
nivolumab (both approved by the FDA), as well as 
trastuzumab/lapatinib 
 
 
 
7 Evidence 
A literature search was conducted on 19 October 2017 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “nivolumab”, “Opdivo”, “L01XC17”, “colon cancer”, 
“colorectal cancer” and “bowel cancer”. The manufacturer was also contact-
ed and submitted two references (one of which had already been identified 
by systematic literature search). A manual search identified 17 additional 
references (web documents and journal articles). 
≥Second-line therapy 
options: 
 
prior irinotecan-based 
therapy 
 
 
prior oxaliplatin 
 
 
 
prior bevacizumab 
 
 
RAS wild-type 
 
 
chemotherapy/ 
monoclonal antibodies  
 
BRAF mutation 
 
MSI mutation 
systematic literature 
search in 5 databases:  
108 hits 
 
manual search: 17 
additional references 
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Overall, 125 references were identified. Included in this report is the follow-
ing study to assess outcomes on clinical efficacy and safety: 
 One phase II study (two parts), assessing nivolumab or nivolumab 
in combination with ipilimumab in patients with metastatic 
dMMR/MSI-H CRC [20-22]. 
The assessment of the risk of bias at the study level and the assessment of 
the methodological quality of the evidence based on the EUnetHTA internal 
validity has not been conducted, since this tool is only for randomised con-
trolled trials (RCTs) [23].  
To evaluate the magnitude of “clinically meaningful benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS version 1.1) was used [24, 25]. Details of the magnitude of the clini-
cally meaningful benefit scale are reported in Table 3. 
 
7.1 Clinical efficacy and safety –  
phase II study 
CheckMate 142 (open-label, ongoing, multicentre, single-arm phase II 
study) was conducted to assess the efficacy and safety of nivolumab or 
nivolumab in combination with ipilimumab in patients with metastatic 
dMMR/MSI-H CRC, who have progressed on or after, or been intolerant of 
at least one previous line of treatment, including fluoropyrimidine and oxal-
iplatin or irinotecan [21, 22]. Reported in the current study are only the in-
terim results for nivolumab monotherapy. At the time of data cut-off (3 Jan-
uary 2017), 74 patients with locally determined dMMR/MSI-H metastatic CRC 
were receiving nivolumab, with a median follow-up of 12.0 months (inter-
quartile range [IQR] 8.6–18.0). Additionally, 36 (49%) of the 74 patients 
were still receiving the study treatment at the time of data cut-off; 38 pa-
tients (51%) discontinued (27 progressed, six had treatment-related toxic ef-
fects, one had adverse events [AEs] unrelated to study drug, one had a max-
imum clinical benefit, one due to patient decision, one due to withdrawal of 
consent, and one due to other reasons). 
A total of 74 patients were enrolled to receive 3 mg/kg dose of nivolumab 
every two weeks until disease progression, death, unacceptable toxic effects, 
withdrawal from the study or study end. Out of these 74 patients who had 
been locally assessed as having dMMR/MSI-H metastatic CRC, 53 (72%) 
patients were centrally determined to have MSI-H tumours and 14 (19%) to 
have non-MSI-H (microsatellite-stable [MSS]/MSI-low) tumours. For seven 
patients (9%) insufficient adequate tumour tissue or DNA was available. 
Therefore, these patients had no centrally determined results. 29 (39%) of 74 
patients were both BRAF and KRAS wild-type, and 12 (16%) had tumours 
with a BRAF mutation.  
Enrolled patients were at least 18 years old and had a median age of 52.5 
(ranging from 44.0–64.0); 57 (77%) of the 74 enrolled patients were younger 
than 65 years. The study population had an Eastern Cooperative Oncology 
Group (ECOG) performance status of 0 and 1 and measurable disease de-
fined by the Response Evaluation Criteria in Solid Tumours (RECIST, ver-
sion 1.1) guidelines. Detailed patient characteristics, including inclusion 
and exclusion criteria, can be found in Table 4. 
overall: 125 references 
included: 1 study 
study level risk of bias 
assessment based on 
EUnetHTA internal 
validity not conducted 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
CheckMate 142: open-
label, ongoing, single-
arm, multicentre phase 
II study 
74 patients with dMMR/ 
MSI-H CRC 
 
centrally determined 
status: 
72% MSI-H 
19% MSS/ MSI-low 
9% undefined 
median age of 52.5 years 
and ECOG performance 
status of 0–2 
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The primary outcome of CheckMate 142 was investigator-assessed objective 
response (OR) as per RECIST 1.1; secondary outcomes included duration of 
response, rate of complete response and masked independent central review-
assessed OR. Other exploratory endpoints included safety and tolerability of 
nivolumab monotherapy; progression-free survival (PFS); overall survival 
(OS); the association between biomarkers, such as PD-L1 expression, with 
nivolumab activity; and quality of life (QoL) changes from baseline. 
 
 
7.1.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of nivolumab on mortality? 
At the time of interim analysis, median OS (23 deaths) had not been reached 
(95% CI 18.0–not estimable [NE]). The 12-month OS was 73% (95% CI 62–
82). 
 
D0006: How does nivolumab affect progression (or recurrence) of colorectal 
cancer? 
Median PFS was 14.3 (95% CI 4.30–NE) months, after 36 investigator-
assessed progression events had happened. The 12-month PFS was 50% 
(95% CI 38–61).  
 
D0005: How does nivolumab affect symptoms and findings (severity, fre-
quency) of colorectal cancer? 
Per investigator assessment, 23 (31.1%, 95% CI 20.8–42.9) of the 74 patients 
who had locally assessed dMMR/MSI-H CRC demonstrated an OR; all of 
them were partial. In total, three responders had experienced progression. In 
51 (69%, 95% CI 57–79) patients a disease control for at least 12 weeks was 
present. An OR assessed by the blinded independent central review (BICR) 
occurred in 24 (32%, 95% CI 22–44) patients (dMMR/MSI-H per local as-
sessment); out of those, 2 (3%) patients had a complete response and 22 
(30%) a partial one. 19 (36%, 95% CI 23–50) patients out of 53 centrally 
identified to have dMMR/MSI-H CRC showed an OR, independent of their 
assessment (by investigator or central review). Out of the 14 patients as-
sessed as having non-MSI-H by the central review, three (21%, 95% CI 5–51) 
had an OR (all partial). 
The median time to response was 2.8 months (IQR 1.4–3.2) for investigator-
assessed patients with locally determined dMMR/MSI-H metastatic CRC. 
All responders were alive at the time of data cut-off and the median duration 
of response had not yet been reached (95% CI NE). 
 
D0011: What is the effect of nivolumab on patients ̕ body functions? 
Nivolumab may affect body functions by causing the following immune-
mediated AEs: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis 
and renal dysfunction, and skin adverse reactions. Furthermore, after the 
primary outcome: OR 
assessed by 
investigators 
median OS had not been 
reached, 12-month OS: 
73% 
median PFS 14.3 months 
(after 36 events) 
investigator-assessed 
OR: 31.1% (all partial) 
 
BICR assessed 
OR: 32% (3% complete 
& 30% partial response) 
median time to response 
2.8 months 
duration of response 
was not reached 
immune-mediated AEs 
 
complications during 
allogeneic HSCT 
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administration of nivolumab, complications can occur due to allogeneic 
hematopoietic stem cell transplantation (HSCT) [3]. 
 
D0012: What is the effect of nivolumab on generic health-related quality of 
life? 
D0013: What is the effect of nivolumab on disease-specific quality of life? 
Until week 97, patient-reported outcomes were measured. Questionnaire 
completion rates ranged from 68% to 100%. No clinically meaningful dete-
rioration (≥10 point change) in functioning or worsening of symptoms and 
global health status or QoL, as per EORTC QLQ-C30, was experienced by 
50% or more patients. At week 13, clinically meaningful improvements 
could be observed in functioning (emotional, role, and social), symptoms (fa-
tigue, pain, insomnia, appetite loss, constipation, and diarrhoea), and global 
QoL. No meaningful improvements in physical functioning, nausea and 
vomiting, or dyspnoea occurred. In addition, clinically relevant worsening in 
cognitive functioning was observed at week 67. 12% of patients reported 
health problems at baseline as per EQ-5D, ranging from 12% (eight of 67 pa-
tients for self-care) to 57% (38 of 67 patients for pain). Notable (>10%) re-
ductions in health problems occurred at week 13 for all dimensions: mobili-
ty, self-care, usual activities, pain/discomfort, and anxiety or depression. 
 
Table 1: Efficacy results of CheckMate 142 study 
Descriptive 
statistics and 
estimate vari-
ability 
Treatment group 
Nivolumab (dMMR/MSI-H per local 
assessment) 
Nivolumab (dMMR/MSI-H per 
central assessment) 
Number of subjects (n) 74 53 
Assessment Investigator 
Blinded 
independent 
central review 
Investigator 
Blinded 
independent 
central review 
Objective response, n (%, 95% CI) 23 (31.1, 20.8–42.9) 24 (32, 22–44) 19 (36, 23–50) 19 (36, 23–50) 
BOR CR, n (%) 0 (0) 2 (3) 0 (0) 1 (2) 
PR, n (%) 23 (31) 22 (30) 19 (36) 18 (34) 
Stable disease, n (%) 28 (38) 25 (34) 20 (37) 19 (36) 
Progressive disease, n 
(%) 
19 (26) 21 (28) 11 (21) 12 (23) 
Not determined, n (%) 4 (5) 4 (5) 3 (6) 3 (6) 
Disease control for ≥12 weeks,  
n (%, 95% CI) 51 (69, 57–79) 47 (64, 52–74) 39 (74, 60–85) 37 (70, 56–82) 
PFS 
Median PFS, months  
(95% CI) 
12-month PFS, % 
(95% CI) 
 
14.3 (4.30–NE) 
 
50 (38-61) 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
OS 
Median OS, months  
(95% CI) 
12-month OS, % 
(95% CI) 
 
NR (18.0–NE) 
 
73 (62-82) 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
Abbreviations: BOR = best overall response, CI = confidence interval, CR = complete response, dMMR/MSI-H = DNA mismatch repair-
deficient/microsatellite instability-high, NA = not available, NE = not estimable, NR = not reached, PFS = progression-free survival, PR = partial 
response, OS = overall survival 
 
≥50% of patients had no 
clinically meaningful 
deterioration in 
functioning or 
worsening of symptoms, 
global health status/QoL 
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7.1.2 Safety 
 
C0008: How safe is nivolumab in relation to the comparator(s)? 
Since the CheckMate 142 study was a single-arm study, no results compar-
ing nivolumab to a comparator are available. However, in 52 patients (70%) 
drug-related AEs occurred; out of those, 15 (20%) patients had grade ≥3 
AEs. Increased lipase (n = 6) and amylase (n = 2) were the only grade ≥3 
AEs that were present in more than one patient. Serious AEs related to the 
study treatment of grade 3 or higher occurred in nine (12%) patients; includ-
ing adrenal insufficiency, increased ALT levels, colitis, diarrhoea, gastritis, 
stomatitis, acute kidney injury, pain, and arthritis.  
One serious AE of sudden death from an unknown cause was observed, but 
was not related to toxic effects of nivolumab. In addition, 20 (27%) patients 
died because of disease progression, three (4%) due to unknown cause, and 
12 (16%) patients died within 100 days after receiving their last dose of 
nivolumab. None of the deaths occurred because of toxic effects of the study 
drug. Discontinuation due to drug-related AEs were present in five (7%) pa-
tients, including increased ALT level, colitis, duodenal ulcer, acute kidney 
injury, and stomatitis. 
 
C0002: Are the harms related to dosage or frequency of applying nivolumab? 
No dose reductions were permitted in the CheckMate 142 study. Dose 
interruptions were allowed for treatment-related AEs, but if the interruption 
lasted longer than six weeks, the patient was discontinued from the study. 
However, no dose interruptions of any patient were reported in the trial.  
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of nivolumab? 
Nivolumab may cause foetal harm, resulting in increased abortions or prem-
ature infant deaths, due to its mechanism of action. It is advised that females 
use effective contraception when they receive nivolumab, and for at least five 
months after the last dosage. In addition, breastfeeding should be discontin-
ued during the treatment [3]. 
 
20% of patients had 
grade ≥3 AEs 
 
most common grade ≥3 
AEs: Increased lipase 
and amylase 
none of the deaths 
occurred due to toxic 
effects of nivolumab 
 
7% of patients 
discontinued because of 
treatment-related AEs 
dose reductions were 
not allowed & 
no dose interruptions 
are reported 
susceptible patient 
group: pregnant or 
breastfeeding women  
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Table 2: Most frequent treatment-related adverse events
1
 in patients locally assessed as having 
dMMR/MSI-H 
Adverse event (according  
to CTCAE version 4.03) 
Nivolumab (n = 74) 
 Grade 1–2 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Any event 36 (49) 13 (18) 2 (3) 
Fatigue 16 (22) 1 (1) 0 (0) 
Diarrhoea 15 (20) 1 (1) 0 (0) 
Pruritus 10 (14) 0 (0) 0 (0) 
Rash 8 (11) 0 (0) 0 (0) 
Nausea 7 (10) 0 (0) 0 (0) 
Hypothyroidism 7 (10) 0 (0) 0 (0) 
Asthenia 5 (7) 0 (0) 0 (0) 
Increased aspartate 
aminotransferase 
5 (7) 0 (0) 0 (0) 
Arthralgia 4 (5) 0 (0) 0 (0) 
Pyrexia 4 (5) 0 (0) 0 (0) 
Dry skin 4 (5) 0 (0) 0 (0) 
Maculopapular rash 4 (5) 1 (1) 0 (0) 
Increased alanine 
aminotransferase 
3 (4) 1 (1) 0 (0) 
Lipase increased 3 (4) 4 (5) 2 (3) 
Amylase increase 2 (3) 2 (3) 0 (0) 
Stomatitis 2 (3) 1 (1) 0 (0) 
Abdominal pain 1 (1) 1 (1) 0 (0) 
Increased creatinine 1 (1) 1 (1) 0 (0) 
Decreased lymphocyte count 1 (1) 1 (1) 0 (0) 
Colitis 0 (0) 1 (1) 0 (0) 
Acute kidney injury 0 (0) 1 (1) 0 (0) 
Adrenal insufficiency 0 (0) 1 (1) 0 (0) 
Oesophagitis 0 (0) 1 (1) 0 (0) 
Increased gamma-
glutamyltransferase 
0 (0) 1 (1) 0 (0) 
Gastritis 0 (0) 1 (1) 0 (0) 
Pain 0 (0) 1 (1) 0 (0) 
Abbreviations: AEs = adverse events, CTCAE = Common Terminology Criteria for Adverse Events, 
dMMR/MSI-H = DNA mismatch repair-deficient/microsatellite instability-high 
 
 
 
                                                             
1
 Reported are grade 1–2 AEs occurring in at least 10% of patients in any treatment 
cohort and all grade 3–4 AEs. 
Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or mi-
crosatellite instability-high (MSI-H) colorectal cancer (CRC) 
LBI-HTA | 2017 19 
7.2 Clinical effectiveness and safety – 
 further studies 
There is no further study available that has investigated nivolumab for the 
treatment of patients with dMMR/MSI-H metastatic CRC. However, the 
second part of the CheckMate 142 study investigates the combination of 
nivolumab and ipilimumab for the treatment of CRC patients with MSI-H 
and non-MSI-H. Data for this combination regimen is only available in 
abstract form, since the study is still ongoing [20]. Included were 27 pa-
tients who received four doses of nivolumab (3 mg/kg) and ipilimumab 
(1 mg/kg), followed by nivolumab monotherapy until disease progression 
or other discontinuation, ≥6 months before the database lock (September 
2016). The primary endpoint was investigator-reported objective response 
rate (ORR) by RECIST 1.1; secondary endpoints were OS and PFS. 
At the time of database lock 44% of patients still remained on treatment, 
and 14 patients had discontinued therapy due to disease progression (n = 8) 
or treatment related AEs (n = 6). The ORR was 41% and the disease control 
rate was 78%. Median time to response was 2.7 months, and 82% of respons-
es (9/11) were still ongoing at 6 months. Median duration of response, PFS 
as well as OS had not been reached. Grade 3–4 treatment related AEs were 
present in 10 patients (37%). 
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of nivolumab? 
In Austria, nivolumab is available as 4 mg and 10 mg concentrated infusion 
solutions. The ex-factory price of 40 mg is € 572; therefore, based on the rec-
ommended dose of 3 mg/kg intravenously every two weeks, assuming an av-
erage body weight of 70 kg, costs of € 6,006 per treatment cycle (four weeks) 
would incur [26]. In the CheckMate 142 trial patients received a median 
number of 22 nivolumab doses, according to this dosage number costs of 
€ 66,066 would arise [21]. Additional costs associated with MSI testing and 
the treatment of AEs will also occur. 
 
 
 
Part 2 of the CheckMate 
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nivolumab (ongoing) 
ORR: 
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grade ≥3 AEs: 37% 
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9 Ongoing research 
In November 2017, a search in databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu was conducted. No ongoing phase III or IV tri-
als investigating nivolumab in colon cancer could be identified. However, 
several phase II studies are ongoing in different treatment lines of colon 
cancer, either using nivolumab monotherapy or combination treatment: 
 NCT03104439: A phase II study investigating nivolumab and 
ipilimumab and radiation therapy in microsatellite stable (MSS) 
and microsatellite instability (MSI) high colorectal and pancreatic 
cancer. Estimated primary completion date is October 2024. 
 NCT02860546: A phase II study with safety lead-in, evaluating 
TAS-102 plus nivolumab in patients with microsatellite stable re-
fractory metastatic colorectal cancer. Estimated primary comple-
tion date is March 2018. 
 NCT03271047: An open-label phase Ib/II study of binimetinib ad-
ministered in combination with nivolumab or nivolumab plus 
ipilimumab in patients with previously treated microsatellite-stable 
(MSS) metastatic colorectal cancer with RAS mutation. Estimated 
primary completion date is January 2020. 
 NCT03026140: A phase II study investigating nivolumab, ipili-
mumab and COX2-inhibition in early stage colon cancer: an unbi-
ased approach for signals of sensitivity: The NICHE TRIAL. Esti-
mated primary completion date is January 2020. 
 NCT03233711: A randomized phase II study of nivolumab after 
combined modality therapy (CMT) in high risk anal cancer. Esti-
mated primary completion date is December 2019. 
 NCT02948348: A Phase Ib/II multicentre study to investigate the 
safety, efficacy and proof of concept (POC) of nivolumab mono-
therapy as a sequential therapy following preoperative chemoradio-
therapy patients with locally advanced resectable rectal cancer. Es-
timated primary completion date is June 2020. 
In addition, nivolumab is currently being investigated in several other indi-
cations, like thymic carcinoma, renal cell carcinoma, transitional cell carci-
noma, myeloma, biliary tract cancer and head and neck neoplasms. 
 
 
 
10 Discussion 
In July 2017, nivolumab has been granted accelerated approval for the 
treatment of patients at the age of 12 or older with dMMR and MSI-H meta-
static CRC, who progressed following treatment with fluoropyrimidine, ox-
aliplatin, and irinotecan in the US [3]. However, nivolumab has not yet re-
no phase III or IV studies 
are ongoing, 
investigating nivolumab 
in patients with colon 
cancer 
 
ongoing phase II studies 
in different treatment 
lines and regimens 
numerous ongoing 
studies investigating 
nivolumab 
nivolumab approved for 
CRC by the FDA, but not 
by the EMA 
Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or mi-
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ceived marketing authorisation by the EMA for the treatment of metastatic 
CRC [5]. 
The FDA approval was based on an open-label, ongoing, multicentre, single-
arm phase II study, the CheckMate 142 [21, 22]. The study is separated into 
two parts, investigating nivolumab monotherapy or nivolumab in combina-
tion with ipilimumab. The part of the study examined in the present report 
was conducted to assess the activity and safety of nivolumab monotherapy in 
74 patients with metastatic dMMR/MSI-H CRC. The results showed that 23 
(31.1%) of the 74 included patients demonstrated an OR – all responses were 
partial (investigator-assessed). An OR assessed by BICR occurred in 24 
(32%) patients (dMMR/MSI-H per local assessment); out of those, 2 (3%) 
patients had a complete response and 22 (30%) a partial one. At the time of 
data cut-off (3 January 2017), all responders were alive. However, the medi-
an duration of response was not reached. After 36 investigator-assessed pro-
gression events had happened, the median PFS was 14.3 (95% CI 4.30–NE) 
months, but was not mature at the time of data cut-off. In addition, median 
OS (23 deaths) had not been reached, at the time of interim analysis. Re-
garding QoL no clinically meaningful deterioration (≥10 point change) in 
functioning or worsening of symptoms and global health status was experi-
enced by 50% or more of the patients (EORTC QLQ-C30). 
Since only interim results are present, mature OS data and further follow-up 
data are needed to ensure a clinical relevant patient benefit over time. In 
addition, since 57 (77%) of the 74 patients were younger than 65 years and 
the median age at diagnosis of CRC is 73 years in men and 75 in women 
(range: 70–75), the study population reflects younger patients than those 
common in clinical practice [16]. In addition, none of the patients had an 
ECOG performance-status higher than 1. Durable responses were observed 
in metastatic CRC patients –however, not only in a younger, but also in a 
less diseased population (ECOG 0–1) – and might not be reached in the gen-
eral patient population. Therefore, this patient population should be further 
analysed in future trials to identify any advantages or disadvantages for old-
er patients with more comorbidities when treated with nivolumab. 
In regard to safety outcomes, drug-related AEs occurred in 70% of patients; 
out of those, 20% of patients had grade ≥3 AEs (most frequent: increased li-
pase and amylase). Serious AEs related to the study treatment of grade 3 or 
higher occurred in 12% of patients. Moreover, 27% of patients died because 
of disease progression and 4% due to unknown cause. None of the deaths oc-
curred because of toxic effects of the study drug. 7% of the patients discon-
tinued treatment due to drug-related AEs (increased ALT level, colitis, duo-
denal ulcer, acute kidney injury, and stomatitis). At the time of data cut-off 
38 patients (51%) were discontinued from the study. 
Given the single-arm design of the CheckMate 142 study, we applied form 3 
(scores 1–3) of the ESMO-MCBS v1.1 in order to assess the clinical benefit 
of nivolumab [24, 25]. The form 3 was introduced into the updated ESMO-
MCBS v1.1 framework to assess studies in orphan diseases and for diseases 
with high unmet need. However, since the scale only ranges from score 1 to 
3, the criteria for a “meaningful clinical benefit” (score 4 or 5) cannot be sat-
isfied by these therapies. The application of the ESMO-MCBS v1.1 to the 
CheckMate 142 study resulted in a grade 3, though it should be emphasised 
that this grade is based on the median PFS (14.3 months), which was not 
mature at the time of data cut-off (36 events, 95% CI 4.30–NE).  
CheckMate 142 
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OR: 32% (3% complete 
& 30% partial response) 
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Moreover, due to the single-arm design of the trial, several limitations have 
to be considered, especially in regard to the interpretation of the treatment 
effect. Not only is a positive effect of the treatment with nivolumab missing, 
but also the comparative efficacy of the treatment. In addition, responses 
may be influenced by an effect of the natural history of the disease [27]. Fur-
thermore, the high discontinuation rate and the single-arm and open-label 
design of the study can also lead to various biases besides the treatment ef-
fect (e.g., bias from patient attrition), that can affect clinical outcomes [28]. 
Nivolumab should therefore be compared to other treatment options (e.g., 
pembrolizumab). This could have the additional advantage of yielding in-
formation as to which treatment option the patients benefit the most from 
and thus enable the establishment of treatment recommendations based on 
direct head-to-head comparison data. 
Furthermore, there was a high discordance of 20% between the local and the 
central assessment of dMMR and MSI. This could be due to the investiga-
tion of tissues at different time points and the use of different methods and 
analyses. In addition, no association between the treatment effect and PD-
L1 expression, KRAS or BRAF mutation or history of Lynch syndrome was 
shown. This highlights the challenges of dMMR and MSI assessments and 
the need of repetitive testing. Furthermore, the establishment of a reliable 
dMMR and MSI biomarker testing will be crucial in the future to select 
those patients who benefit most from nivolumab [29].  
In a current study, PD-1 therapy-resistant melanoma patients demonstrated 
unique signatures of upregulated genes involved in immunosuppression, 
angiogenesis, monocyte and macrophage chemotaxis, extracellular matrix 
remodelling, and epithelial–mesenchymal transition. The factor of re-
sistance may be eliminated by combined targeting of these pathways with 
PD-1 and other agents, thus producing effective antitumor immunity [30]. 
Therefore, results from the second part of the CheckMate 142 study, which 
investigates the addition of ipilimumab to nivolumab, are of high im-
portance to further elucidate the issue of resistance. 
The costs of a four-week treatment cycle would be (assuming an average 
body weight of 70 kg) € 6,006 [26]. Costs for about 22 doses may arise, since 
this was the median number of nivolumab doses in the CheckMate 142 
study. According to this, the total costs for 22 doses of nivolumab would be € 
66,066. However, additional costs for the treatment of AEs, as well as costs 
associated with MSI testing, would arise. 
Overall, the treatment of nivolumab offers durable responses; 31.1% demon-
strated partial responses with an acceptable safety profile at high costs. 
However, the immature OS data, in combination with the lack of evidence 
for the actual patient population affected most by CRC in clinical practice 
and the potential resistance mechanism, highlight the requirement for long-
term data. Moreover, head-to-head comparisons (e.g., pembrolizumab) will 
be necessary to identify the best treatment option for CRC patients with 
dMMR/MSI-H and to be able to reliably interpret the actual treatment ef-
fect. Finally, trustworthy biomarker testing will be needed to select those pa-
tients who benefit most from nivolumab. 
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Table 3: Benefit assessment based on the ESMO-MCBS v1.1 [24, 25] 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form MG-ST 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Original 
ESMO-
MCBS 
nivolumab CRC NC ORR 3 x 
ORR: 31.1% 
PFS: 14.3 PFS: 4.30–NE PFS ≥6 months 3 x ND x 3 
Abbreviations: 
A
 = co-primary endpoints, AJ = Adjustments, CCR = colorectal cancer, CI = confidence interval, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, 
ND = no difference, ORR = objective response rate, PE = primary endpoint, PFS = progression-free survival, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life, ST = standard treatment 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
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Table 4: Characteristics of CheckMate 142 study 
Title: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer: 
an open-label, multicentre, phase 2 study [21, 22] 
Study identifier NCT02060188, EudraCT number 2013-003939-30, CA209-142 
Design Phase II, single-arm, open-label, multicentre 
Duration Enrolment: March 2014 to March 2016 
 Median follow-up: 12.0 months (range: 8.6-18.0) 
 Data cut-off: 2017-01-03 
Hypothesis 
Exploratory 
The study was designed as a phase II trial to investigate the activity and safety of nivolumab mon-
otherapy or nivolumab in combination with ipilimumab in patients with MSI-H and non-MSI-H 
metastatic colorectal cancer. If fewer than seven of the first 19 patients with centrally confirmed 
MSI-H metastatic colorectal cancer had an objective response (complete response or partial re-
sponse) with nivolumab, enrolment would end; if seven or more patients had a response, 29 addi-
tional centrally confirmed patients would be treated in stage 2. 
Funding Bristol-Myers Squibb 
Treatments group Investigation (n = 74) 
Dose of 3 mg/kg nivolumab monotherapy intravenously 
every 2 weeks until disease progression, death, unaccepta-
ble toxic effects, withdrawal of consent or study end 
Endpoints and definitions Objective re-
sponse (primary 
endpoint) 
- 
Assessed by the investigator according to RECIST criteria 
Overall response OR 
Best response between the date of first dose and progres-
sion or subsequent treatment, whichever occurred first, 
divided by the number of those treated 
Investigator-
assessed objective 
response 
- Characterised by the investigator-assessed duration of re-
sponse and rate of complete response 
Duration of re-
sponse 
DOR 
Time from first confirmed response (complete response or 
partial response) to the date of tumour progression or 
death due to any cause, whichever occurred first 
Masked inde-
pendent central 
review-assessed 
objective re-
sponse 
- 
Number of patients with a best overall response of con-
firmed complete response or partial response, according to 
RECIST criteria, divided by the number of those treated 
Progression-free 
survival 
PFS 
Time from first dosing date to the date of the first docu-
mented progression, or death due to any cause, whichever 
occurred first 
Overall survival OS Time from first dosing date to the date of death, 
Quality of life QoL 
Changes from baseline functioning (emotional, role, and 
social), symptoms (fatigue, pain, insomnia, appetite loss, 
constipation, and diarrhoea), cognitive functioning and 
global quality of life 
Results and analysis 
Analysis description Primary analysis 
An adequate number of objective responses (n = 7) was achieved in the first 19 patients with cen-
trally confirmed dMMR/MSI-H metastatic colorectal cancer given nivolumab in stage 1; therefore, 
enrolment into stage 2 was initiated and is now complete. 
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Title: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer: 
an open-label, multicentre, phase 2 study [21, 22] 
Study identifier NCT02060188, EudraCT number 2013-003939-30, CA209-142 
Analysis population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion 
 Histologically confirmed metastatic or recurrent colorectal cancer with 
tumours locally assessed as dMMR or MSI-H 
 Age ≥ 18 years 
 ECOG performance status of 0 or 1 
 Measurable disease defined by the RECIST, version 1.1 
 Patients must have progressed on or after, or been intolerant of at least 
one previous line of treatment, including fluoropyrimidine and oxali-
platin or irinotecan. 
 Baseline laboratory tests required to assess eligibility included with 
blood cell counts, neutrophils, platelets, haemoglobin, serum creatinine, 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), total 
bilirubin, blood urea nitrogen (BUN), lipase and amylase 
 
Exclusion 
 Active brain metastases or leptomeningeal metastases 
 Any serious or uncontrolled medical disorder that might have resulted in 
an increased risk associated with participation in the study or study drug 
administration, that impaired the ability of the patient to receive 
nivolumab, or that interfered with the interpretation of study results 
 Previous cancer active within the previous 3 years 
 Active, known, or suspected autoimmune disease (except for vitiligo, 
type 1 diabetes mellitus, residual hyperthyroidism due to autoimmune 
condition requiring only hormone replacement, psoriasis not requiring 
systemic treatment, or conditions not expected to recur in the absence of 
an external trigger) 
 Need for immunosuppressive doses of systemic corticosteroids or other 
immunosuppressive drugs 2 weeks before nivolumab administration 
 Previous treatment with other therapy targeting T-cell costimulation or 
immune checkpoint pathways 
 Acute or chronic hepatitis B or hepatitis C virus infection or history of 
positive testing for HIV or known AIDS 
 Previous palliative radiotherapy allowed if completed at least 2 weeks be-
fore study drug administration per the protocol 
 
Characteristics 
 
 
dMMR/MSI-H per local assessment  
(n = 74) 
 
Age 
Median, years (range) 
<65 years, n (%) 
 
52.5 (44.0-64.0) 
57 (77) 
Sex 
Male, n (%) 
Female, n (%) 
 
44 (59) 
30 (41) 
Race 
White, n (%) 
Black, n (%) 
Asian, n (%) 
Other, n (%) 
 
65 (88) 
7 (9) 
1 (1) 
1 (1) 
ECOG performance status 
0, n (%) 
1, n (%) 
 
32 (43) 
42 (57) 
Disease stage at diagnosis (TNM stage) 
I-II, n (%) 
III, n (%) 
IV, n (%) 
 
15 (20) 
26 (35) 
33 (45) 
Number of previous regimens received 
0, n (%) 
1, n (%) 
2, n (%) 
≥3, n (%) 
 
1 (1) 
11 (15) 
22 (30) 
40 (54) 
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Title: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer: 
an open-label, multicentre, phase 2 study [21, 22] 
Study identifier NCT02060188, EudraCT number 2013-003939-30, CA209-142 
Analysis population 
(continuation)  
Previous treatments received 
Fluoropyrimidine (fluorouracil or capecitabine), n (%) 
Oxaliplatin, n (%) 
VEGF inhibitors, n (%) 
Irinotecan, n (%) 
EGFR inhibitors, n (%) 
Regorafenib, n (%) 
Other, n (%) 
 
73 (99) 
71 (96) 
57 (77) 
55 (74) 
31 (42) 
12 (16) 
11 (15) 
Previous radiotherapy, n (%) 27 (36) 
Mutation status 
Both BRAF and KRAS wild-type, n (%) 
BRAF mutation, n (%) 
KRAS mutation, n (%) 
Unknown, n (%) 
 
29 (39) 
12 (16) 
26 (35) 
7 (9) 
Tumour PD-L1 expression quantifiable at baseline 
≥1%, n (%) 
<1%, n (%) 
Unknown, n (%) 
 
21 (28) 
47 (64) 
6 (8) 
Clinical history of Lynch syndrome 
Yes, n (%) 
No, n (%) 
Unknown, n (%) 
 
27 (36) 
28 (38) 
19 (26) 
Study strengths  The study represents the largest cohort of patients with dMMR/MSI-H metastatic colorectal 
cancer given an immune checkpoint inhibitor. 
 Responses were recorded across all patient subgroups, including those with (≥1%) and 
without (<1%) tumour PD-L1 expression. 
 Responses were reported in patients with and without a clinical history of Lynch syndrome, 
or KRAS or BRAF mutations. 
 dMMR/MSI-H status was determined locally before inclusion based on archival tissue using 
PCR or immunohistochemistry and assessed centrally by PCR (modified Bethesda criteria) 
using tumour tissue collected at baseline. 
 Patient population of the study also represents a young metastatic colorectal cancer 
population. 
Study limitations  Insufficient follow-up to determine intended effects (immature median PFS and OS) 
 Patient subgroups were small, which could limit the interpretation of the subgroup analyses. 
 The study population reflects younger patients with less comorbidities than those common 
in clinical practice. 
 Absence of a comparator group 
Abbreviations: dMMR/MSI-H = DNA mismatch repair-deficient/microsatellite instability-high, DOR = duration of response, ECOG =Eastern 
Cooperative Oncology Group, EGFR =Epidermal Growth Factor Receptor, OR = overall response, OS = overall survival, PFS = progression-
free survival, QoL = quality of life, RECIST = Response Evaluation Criteria in Solid Tumours, TNM = Classification of Malignant Tumours, 
VEGF = Vascular Endothelial Growth Factor 
